Literature DB >> 11758762

The cellular uptake and metabolism of clodronate in RAW 264 macrophages.

H Mönkkönen1, M J Rogers, N Makkonen, S Niva, S Auriola, J Mönkkönen.   

Abstract

PURPOSE: Non-nitrogen-containing bisphosphonates, such as clodronate (dichloromethylene bisphosphonate), appear to act as prodrugs, their active form being the AppCp-type analogues of ATP. To further elucidate this, we examined the cellular uptake of clodronate and intracellular accumulation of the metabolite of clodronate (AppCCl2p) in RAW 264 macrophages, the influence of clodronate metabolism on the intracellular ATP concentration, and the time course of clodronate metabolism and the effects of clodronate on cytokine secretion from macrophages.
METHODS: The cellular uptake of clodronate was measured using 14C-labeled clodronate. AppCCl2p was determined in cell extracts by using an ion-pairing HPLC-ESI-MS. The cytokine concentrations in the culture supernatants were measured with time-resolved fluoroimmunoassay. Intracellular ATP concentration was measured with a luminometer using a luciferin-luciferase assay.
RESULTS: Of the clodronate internalized by macrophages in vitro, 30-55% is metabolized to AppCCl2p, which accumulates to high intracellular concentrations during the first 12 h of exposure. This accumulation does not affect the ATP levels in the cells. The time course of metabolite appearance in the cells and the inhibition of cytokine secretion were very similar.
CONCLUSIONS: These results strongly support the idea that clodronate acts as a prodrug, the active form being its intracellular AppCCl2p metabolite.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11758762     DOI: 10.1023/a:1013026313647

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  27 in total

1.  The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis.

Authors:  J C Frith; J Mönkkönen; S Auriola; H Mönkkönen; M J Rogers
Journal:  Arthritis Rheum       Date:  2001-09

2.  Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes.

Authors:  M J Rogers; R J Brown; V Hodkin; G M Blackburn; R G Russell; D J Watts
Journal:  Biochem Biophys Res Commun       Date:  1996-07-25       Impact factor: 3.575

3.  Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.

Authors:  J C Frith; J Mönkkönen; G M Blackburn; R G Russell; M J Rogers
Journal:  J Bone Miner Res       Date:  1997-09       Impact factor: 6.741

4.  Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis.

Authors:  P J Richards; A S Williams; R M Goodfellow; B D Williams
Journal:  Rheumatology (Oxford)       Date:  1999-09       Impact factor: 7.580

5.  Long-term amelioration of rat adjuvant arthritis following systemic elimination of macrophages by clodronate-containing liposomes.

Authors:  R W Kinne; C B Schmidt-Weber; R Hoppe; E Buchner; E Palombo-Kinne; E Nürnberg; F Emmrich
Journal:  Arthritis Rheum       Date:  1995-12

Review 6.  Bisphosphonates: a review of their pharmacokinetic properties.

Authors:  J H Lin
Journal:  Bone       Date:  1996-02       Impact factor: 4.398

7.  Cytotoxicity of dichloromethane diphosphonate and of 1-hydroxyethane-1,1-diphosphonate in the amoebae of the slime mould Dictyostelium discoideum. A 31P NMR study.

Authors:  S Pelorgeas; J B Martin; M Satre
Journal:  Biochem Pharmacol       Date:  1992-12-01       Impact factor: 5.858

8.  Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro.

Authors:  J Mönkkönen; M Taskinen; S O Auriola; A Urtti
Journal:  J Drug Target       Date:  1994       Impact factor: 5.121

9.  Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro.

Authors:  N Pennanen; S Lapinjoki; A Urtti; J Mönkkönen
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

10.  Macrophage-like RAW 264 cell line and time-resolved fluoroimmunoassay (TRFIA) as tools in screening drug effects on cytokine secretion.

Authors:  N Pennanen; S Lapinjoki; A Palander; A Urtti; J Mönkkönen
Journal:  Int J Immunopharmacol       Date:  1995-06
View more
  8 in total

1.  Bisphosphonate-Generated ATP-Analogs Inhibit Cell Signaling Pathways.

Authors:  Satish R Malwal; Bing O'Dowd; Xinxin Feng; Petri Turhanen; Christopher Shin; Jiaqi Yao; Boo Kyung Kim; Noman Baig; Tianhui Zhou; Sandhya Bansal; Rahul L Khade; Yong Zhang; Eric Oldfield
Journal:  J Am Chem Soc       Date:  2018-06-05       Impact factor: 15.419

2.  Pharmacokinetic profile of bisphosphonates in the treatment of metabolic bone disorders.

Authors:  Luigi Sinigaglia; Massimo Varenna; Silvia Casari
Journal:  Clin Cases Miner Bone Metab       Date:  2007-01

3.  A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates.

Authors:  Hannu Mönkkönen; Seppo Auriola; Petri Lehenkari; Maarit Kellinsalmi; Ilmo E Hassinen; Jouko Vepsäläinen; Jukka Mönkkönen
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

4.  Preclinical evaluation of an innovative anti-TAM approach based on zoledronate-loaded erythrocytes.

Authors:  Raffaella Sabatino; Serafina Battistelli; Mauro Magnani; Luigia Rossi
Journal:  Drug Deliv Transl Res       Date:  2018-10       Impact factor: 4.617

Review 5.  Tumour macrophages as potential targets of bisphosphonates.

Authors:  Thea L Rogers; Ingunn Holen
Journal:  J Transl Med       Date:  2011-10-17       Impact factor: 5.531

6.  RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro.

Authors:  Karen A Sutherland; Helena L Rogers; Denise Tosh; Michael J Rogers
Journal:  Arthritis Res Ther       Date:  2009-04-30       Impact factor: 5.156

7.  Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cells.

Authors:  Raffaella Sabatino; Antonella Antonelli; Serafina Battistelli; Reto Schwendener; Mauro Magnani; Luigia Rossi
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

8.  Abnormal Cannabidiol Affects Production of Pro-Inflammatory Mediators and Astrocyte Wound Closure in Primary Astrocytic-Microglial Cocultures.

Authors:  Julian Cardinal von Widdern; Tim Hohmann; Faramarz Dehghani
Journal:  Molecules       Date:  2020-01-23       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.